Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study()()

Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). Recurrence after resection of colorectal liver metastases (CRLMs), presumably caused by VEGF-mediated outgrowth of micrometastases, might decrease when VEGF is inhibited. This study examines the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Snoeren, Nikol, van Hillegersberg, Richard, Schouten, Sander B., Bergman, Andre M., van Werkhoven, Erikv, Dalesio, Otilia, Tollenaar, Rob A.E.M., Verheul, Henk M., van der Sijp, Joost, Borel Rinkes, Inne H.M., Voest, E.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237801/
https://www.ncbi.nlm.nih.gov/pubmed/28088688
http://dx.doi.org/10.1016/j.neo.2016.08.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237801/
https://www.ncbi.nlm.nih.gov/pubmed/28088688
http://dx.doi.org/10.1016/j.neo.2016.08.010

Ejemplares similares